Investigational Drug Information for Ensifentrine
✉ Email this page to a colleague
What is the drug development status for Ensifentrine?
Ensifentrine is an investigational drug.
There have been 8 clinical trials for Ensifentrine.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 29th 2020.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Verona Pharma plc, Iqvia Pty Ltd, and Nuance Pharma (shanghai) Co., Ltd.
There are twenty-one US patents protecting this investigational drug and three hundred and forty-eight international patents.
Summary for Ensifentrine
| US Patents | 21 |
| International Patents | 348 |
| US Patent Applications | 85 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 2 (2020-09-29) |
| Vendors | 31 |
Recent Clinical Trials for Ensifentrine
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects | Nuance Pharma (shanghai) Co., Ltd | Phase 1 |
| A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Laboratory Corporation of America | Phase 3 |
| A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Nuance Pharma (shanghai) Co., Ltd | Phase 3 |
Clinical Trial Summary for Ensifentrine
Top disease conditions for Ensifentrine
Top clinical trial sponsors for Ensifentrine
US Patents for Ensifentrine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ensifentrine | ⤷ Try a Trial | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | ⤷ Try a Trial |
| Ensifentrine | ⤷ Try a Trial | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Try a Trial |
| Ensifentrine | ⤷ Try a Trial | Chemical compounds | AstraZeneca AB (Sodertalje, SE) | ⤷ Try a Trial |
| Ensifentrine | ⤷ Try a Trial | Salt of a pyrimido[6,1-A]isoquinolin-4-one compound | VERONA PHARMA PLC (Cardiff, GB) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ensifentrine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ensifentrine | Australia | AU2013227351 | 2032-02-28 | ⤷ Try a Trial |
| Ensifentrine | Australia | AU2016202881 | 2032-02-28 | ⤷ Try a Trial |
| Ensifentrine | Australia | AU2017213466 | 2032-02-28 | ⤷ Try a Trial |
| Ensifentrine | Canada | CA2865702 | 2032-02-28 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
